On July 6, WuXi AppTec rose 3.14% in regular trading, trading at 160.5 HKD/share, with turnover of 3.11 billion HKD.

On the news front, the life sciences tools and services sector rallied collectively, with WuXi XDC up 6.4%, XtalPi up 6.71%, and GenScript Biotech up 5.95%, while Morgan Stanley raised its H-share target price from 155 HKD to 168 HKD and reaffirmed the stock as its top pick.

Morgan Stanley lifted its adjusted earnings forecasts for the company from fiscal year 2026 to 2028 by 4% to 6%, implying a compound annual growth rate of 16%. The bank expects the company's strong performance to continue through 2027, with potential upward revisions to full-year guidance. Additionally, the company has completed both its 1 billion RMB A-share buyback and 2.5 billion HKD H-share buyback programs, with repurchased shares designated for employee stock ownership plans, signaling management confidence in intrinsic value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)